Oculis Completes Last Patient Visit In Phase 3 DIAMOND For OCS-01 Eye Drops In D. Macular Edema

Oculis Holding AG completed the final patient visit in the Phase 3 DIAMOND program for OCS-01, its lead investigational eye drop for diabetic macular edema. The company said it expects to report topline results next, which makes this a routine but important clinical milestone rather than a data readout. The update is modestly constructive for the pipeline but not yet a catalyst.

Analysis

Oculis Holding AG completed the final patient visit in the Phase 3 DIAMOND program for OCS-01, its lead investigational eye drop for diabetic macular edema. The company said it expects to report topline results next, which makes this a routine but important clinical milestone rather than a data readout. The update is modestly constructive for the pipeline but not yet a catalyst.